文献速递神经肌肉病

VEGFR酪氨酸激酶抑制剂与周围神经病变的荟萃分析

Neuropathy with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A meta-analysis.
PubMed 文献 · Neurology · 2019-06-05

结果显示,与安慰剂相比,VEGFR-TKIs增加周围神经病变风险(RR 1.76),感觉神经病变风险亦升高(RR 1.61)。与对照相比,高级别神经病变和高级别感觉神经病变风险均显著增加。

要点

  • VEGFR-TKIs治疗与周围神经病变风险升高相关(RR 1.76)。
  • 感觉神经病变风险亦增加,尤其见于单药治疗时(RR 1.61)。
  • 高级别神经病变风险较对照增加(RR 1.28)。

核心结论

  • VEGFR-TKIs治疗似乎与周围神经病变风险增加相关。

主要发现

  • 与安慰剂相比,VEGFR-TKIs与周围神经病变风险升高相关(RR 1.76;95%CI 1.13-2.75;p=0.01)。
  • VEGFR-TKIs单药治疗与感觉神经病变风险升高相关(RR 1.61;95%CI 1.09-2.37;p=0.02)。
  • 与对照(安慰剂或标准化疗)相比,VEGFR-TKIs的周围神经病变风险更高(RR 1.08;95%CI 1.01-1.15;p=0.03)。
  • 高级别神经病变(RR 1.28;95%CI 1.06-1.54;p<0.01)和高级别感觉神经病变(RR 1.38;95%CI 1.09-1.74;p<0.01)在接受VEGFR-TKIs治疗者中更常见。

临床怎么用

  • 使用VEGFR-TKIs的癌症患者应监测周围神经病变,尤其关注感觉神经症状。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To explore the association of peripheral neuropathy with vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) use in patients with cancer. METHODS: Published data search up to November 2018 reporting peripheral neuropathy in patients with cancer treated with VEGFR-TKIs was performed. The primary outcome was presence of peripheral neuropathy at the end of the trial. Random-effects meta-analysis was performed to estimate relative risk (RR) of individual treatment. RESULTS: Thirty randomized clinical trials (RCTs) including 12,490 patients with cancer were included in this analysis. Eight studies compared VEGFR-TKIs with placebo and the remaining studies compared VEGFR-TKIs with the standard chemotherapeutic regimen. When compared against placebo, VEGFR-TKIs were associated with a higher risk of peripheral neuropathy (RR 1.76; 95% confidence interval [CI] 1.13-2.75, p = 0.01). Similarly, a stronger association was noted for sensory neuropathy with VEGFR-TKIs monotherapy (RR 1.61; 95% CI 1.09-2.37, p = 0.02). Risk of peripheral neuropathy with VEGFR-TKIs was higher even when they were compared against control (either placebo or standard chemotherapeutic agents) (RR 1.08; 95% CI 1.01-1.15, p = 0.03). High-grade neuropathy (RR 1.28; 95% CI 1.06-1.54, p <0.01) and high-grade sensory neuropathy (RR 1.38; 95% CI 1.09-1.74, p < 0.01) were noted more frequently with VEGFR-TKIs treatment compared against control. CONCLUSIONS: VEGFR-TKIs therapy appeared to be associated with an increased risk of neuropathy.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Roy B, Das A, Ashish K, et al. Neuropathy with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A meta-analysis. Neurology. 2019. PMID: 31167931. doi:10.1212/WNL.0000000000007743

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。